[Docetaxel for octogerian metastatic castration-resistant prostate cancer patient: A multicentric ten years' experience].

There is very few data about the management of elderly patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to analyze the management of patients aged 80 and over treated with docetaxel for a mCRPC.

Clinical and pathological characteristics of octogerians treated with docetaxel were collected retrospectively from 3 French centers from 2009 to 2019. Patient's outcome, treatments administered before and/or after docetaxel were also analyzed.

Data of 89 patients could be analyzed. A total of 20.2 % of patients received the standard regimen and 79.8 % received an adapted one. Patients in the adapted group were significantly older than in standard one. Other patient's characteristics - including the geriatric scales - were similar. Dose reductions for toxicity were more frequent in the standard group (P=0.04). The median overall survival of the total population was 13.3 months. It was longer in the standard group than in the adapted group (26.1 months vs 12.4 months=0.01). In multivariate analysis, the type of docetaxel regimen (standard versus adapted) was an independent predictor of survival.

This study suggests the benefit of the standard management even in oldest patients. A geriatric evaluation should certainly be processed in patients with poor oncogeriatric scale in order to select the sub-population able to receive the full dose standard docetaxel regimen.

Bulletin du cancer. 2019 Dec 31 [Epub ahead of print]

Edouard Chanal, Amal Bousarsar, Alexis Vallard, Benoite Méry, Lionel Vincent, Aude Flechon, Anne-Françoise Chanelière, Elisabeth Daguenet, Wafa Bouleftour, Cécile Vassal, Nicolas Magné, Aline Guillot

Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France., Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France., Centre hospitalier de Roanne, département d'oncologie, 28, rue de Charlieu, 42300 Roanne, France., Centre Léon-Bérard, département d'oncologie, 28, promenade Léa et Napoléon-Bullukian, 69008 Lyon, France., Centre hospitalo-universitaire Nord de Saint-Étienne, département de gériatrie, avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France., Institut de cancérologie Lucien-Neuwirth, département universitaire de recherche et d'enseignement, 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France., Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France. Electronic address: .